Antitumor Activity of the Chinese Medicine JC-001 Is Mediated by Immunomodulation in a Murine Model of Hepatocellular Carcinoma
Open Access
- 3 October 2016
- journal article
- research article
- Published by SAGE Publications in Integrative Cancer Therapies
- Vol. 16 (4) , 516-525
Abstract
JC-001 is a Chinese medicine that has been used to treat liver disease; however, its significance in cancer treatment has not been characterized. In this study, we used an immunocompetent tumor model to characterize the antitumor activity of JC-001. A total of 48 Hepa 1-6 tumor-bearing C57BL/6 mice were randomly grouped into 4 groups and treated with H2O or JC-001 via oral administration. After hepatoma cell lines, including HepG2, Hep3B, SK-Hep-1, and Hepa 1-6, underwent 96 hours of JC-001 treatment, a low cytotoxic effect was observed. In contrast, no direct cytotoxic effect of JC-001 on a normal human liver cell line, THLE-3, was observed under the same incubation conditions. Using a murine tumor model, we found that tumor growth could be inhibited by JC-001 in C57BL/6 mice but not in immunodeficient mice. Histopathological analysis of tumors from C57BL/6 mice revealed immune cell infiltration in tumors from the JC-001–treated group, as observed by hematoxylin and eosin staining; in addition, Ki67, hypoxia-inducible factor-1-α, and high mobility group box 1 expression levels were suppressed in the tumors. Both the coculture assay and murine spleen mRNA quantitative PCR analyses demonstrated that JC-001 could suppress Th17 immunity. Our data suggest that JC-001 is a Chinese medicine with low cytotoxicity that can significantly suppress tumor growth by immune regulation. This herbal remedy has great potential for future clinical application in hepatoma therapy.Keywords
This publication has 46 references indexed in Scilit:
- Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammationJournal of Clinical Investigation, 2013
- Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoringTumor Biology, 2013
- Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity?Trends in Molecular Medicine, 2012
- Hepatocellular CarcinomaNew England Journal of Medicine, 2011
- Myeloid Cells in the Tumor Microenvironment: Modulation of Tumor Angiogenesis and Tumor InflammationJournal of Oncology, 2010
- High-mobility group box 1 and cancerBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- The Biological Functions of T Helper 17 Cell Effector Cytokines in InflammationImmunity, 2008
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006
- Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineagesNature Immunology, 2005